Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via "Antigen Capsid-Incorporation" strategy

被引：7

作者：

Gu, Linlin ^{[1
]}

Krendelchtchikova, Valentina ^{[1
]}

Krendelchtchikov, Alexandre ^{[1
]}

Farrow, Anitra L. ^{[1
]}

Derdeyn, Cynthia A. ^{[2
,3
]}

Matthews, Qiana L. ^{[1
,4
]}

机构：

[1] Univ Alabama Birmingham, Div Infect Dis, Dept Med, Birmingham, AL 35294 USA

[2] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30329 USA

[3] Emory Univ, Emory Vaccine Ctr, Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA

[4] Univ Alabama Birmingham, Ctr AIDS Res, Birmingham, AL 35294 USA

来源：

VIROLOGY | 2016年 / 487卷

基金：

美国国家卫生研究院;

关键词：

HIV-1; vaccine; Adenoviral (Ad) vector; Antigen Capsid-Incorporation" strategy; Variable loop2 (V2); Humoral immunity; IgG isotypes; EFFICACY TRIAL; DOUBLE-BLIND; VACCINE; ANTIBODIES; IMMUNOGENICITY; PROTECTION; ACQUISITION; CHALLENGE; INFECTION; SAFETY;

D O I：

10.1016/j.virol.2015.10.010

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Adenoviral (Ad) vectors in combination with the "Antigen Capsid-Incorporation" strategy have been applied in developing HIV-1 vaccines, due to the vectors' abilities in incorporating and inducing immunity of capsid-incorporated antigens. Variable loop 2 (V2)-specific antibodies were suggested in the RV144 trial to correlate with reduced HIV-1 acquisition, which highlights the importance of developing novel HIV-1 vaccines by targeting the V2 loop. Therefore, the V2 loop of HIV-1 has been incorporated into the Ad capsid protein. We generated adenovirus serotype 5 (Ad5) vectors displaying variable loop 2 (V2) of HIV-1 gp120, with the "Antigen Capsid-Incorporation" strategy. To assess the incorporation capabilities on hexon hypervariable region! (HVR1) and protein IX (pIX), 20aa or full length (43aa) of V2 and V1V2 (67aa) were incorporated, respectively. Immunizations with the recombinant vectors significantly generated antibodies against both linear and discontinuous V2 epitopes. The immunizations generated durable humoral immunity against V2. This study will lead to more stringent development of various serotypes of adenovirus-vectored V2 vaccine candidates, based on breakthroughs regarding the immunogenicity of V2. (C) 2015 Published by Elsevier Inc.

引用

页码：75 / 84

页数：10

共 37 条

[1] Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D [J].

Abbink, Peter ;

Lemckert, Angelique A. C. ;

Ewald, Bonnie A. ;

Lynch, Diana M. ;

Denholtz, Matthew ;

Smits, Shirley ;

Holterman, Lennart ;

Damen, Irma ;

Vogels, Ronald ;

Thorner, Anna R. ;

O'Brien, Kara L. ;

Carville, Angela ;

Mansfield, Keith G. ;

Goudsmit, Jaap ;

Havenga, Menzo J. E. ;

Barouch, Dan H. .

JOURNAL OF VIROLOGY, 2007, 81 (09) :4654-4663

[2] First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001) [J].

Baden, Lindsey R. ;

Walsh, Stephen R. ;

Seaman, Michael S. ;

Tucker, Robert P. ;

Krause, Kathleen H. ;

Patel, Alka ;

Johnson, Jennifer A. ;

Kleinjan, Jane ;

Yanosick, Katherine E. ;

Perry, James ;

Zablowsky, Elise ;

Abbink, Peter ;

Peter, Lauren ;

Iampietro, M. Justin ;

Cheung, Ann ;

Pau, Maria G. ;

Weijtens, Mo ;

Goudsmit, Jaap ;

Swann, Edith ;

Wolff, Mark ;

Loblein, Hayley ;

Dolin, Raphael ;

Barouch, Dan H. .

JOURNAL OF INFECTIOUS DISEASES, 2013, 207 (02) :240-247

[3] Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys [J].

Barouch, Dan H. ;

Liu, Jinyan ;

Li, Hualin ;

Maxfield, Lori F. ;

Abbink, Peter ;

Lynch, Diana M. ;

Iampietro, M. Justin ;

SanMiguel, Adam ;

Seaman, Michael S. ;

Ferrari, Guido ;

Forthal, Donald N. ;

Ourmanov, Ilnour ;

Hirsch, Vanessa M. ;

Carville, Angela ;

Mansfield, Keith G. ;

Stablein, Donald ;

Pau, Maria G. ;

Schuitemaker, Hanneke ;

Sadoff, Jerald C. ;

Billings, Erik A. ;

Rao, Mangala ;

Robb, Merlin L. ;

Kim, Jerome H. ;

Marovich, Mary A. ;

Goudsmit, Jaap ;

Michael, Nelson L. .

NATURE, 2012, 482 (7383) :89-U115

[4] Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial [J].

Buchbinder, Susan P. ;

Mehrotra, Devon V. ;

Duerr, Ann ;

Fitzgerald, Daniel W. ;

Mogg, Robin ;

Li, David ;

Gilbert, Peter B. ;

Lama, Javier R. ;

Marmor, Michael ;

del Rio, Carlos ;

McElrath, M. Juliana ;

Casimiro, Danilo R. ;

Gottesdiener, Keith M. ;

Chodakewitz, Jeffrey A. ;

Corey, Lawrence ;

Robertson, Michael N. .

LANCET, 2008, 372 (9653) :1881-1893

[5] Poxvirus vectors as HIV/AIDS vaccines in humans [J].

Elena Gomez, Carmen ;

Perdiguero, Beatriz ;

Garcia-Arriaza, Juan ;

Esteban, Mariano .

HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (09) :1192-1207

[6]

Gómez-Román VP, 2006, JAIDS-J ACQ IMM DEF, V43, P270

[7] Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals [J].

Gorny, Miroslaw K. ;

Pan, Ruimin ;

Williams, Constance ;

Wang, Xiao-Hong ;

Volsky, Barbara ;

O'Neal, Timothy ;

Spurrier, Brett ;

Sampson, Jared M. ;

Li, Liuzhe ;

Seaman, Michael S. ;

Kong, Xiang-Peng ;

Zolla-Pazner, Susan .

VIROLOGY, 2012, 427 (02) :198-207

[8] Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial [J].

Gottardo, Raphael ;

Bailer, Robert T. ;

Korber, Bette T. ;

Gnanakaran, S. ;

Phillips, Joshua ;

Shen, Xiaoying ;

Tomaras, Georgia D. ;

Turk, Ellen ;

Imholte, Gregory ;

Eckler, Larry ;

Wenschuh, Holger ;

Zerweck, Johannes ;

Greene, Kelli ;

Gao, Hongmei ;

Berman, Phillip W. ;

Francis, Donald ;

Sinangil, Faruk ;

Lee, Carter ;

Nitayaphan, Sorachai ;

Rerks-Ngarm, Supachai ;

Kaewkungwal, Jaranit ;

Pitisuttithum, Punnee ;

Tartaglia, James ;

Robb, Merlin L. ;

Michael, Nelson L. ;

Kim, Jerome H. ;

Zolla-Pazner, Susan ;

Haynes, Barton F. ;

Mascola, John R. ;

Self, Steve ;

Gilbert, Peter ;

Montefiori, David C. .

PLOS ONE, 2013, 8 (09)

[9] Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2h study [J].

Gray, Glenda E. ;

Allen, Mai ;

Moodie, Zoe ;

Churchyard, Gavin ;

Bekker, Linda-Gail ;

Nchabeleng, Maphoshane ;

Mlisana, Koleka ;

Metch, Barbara ;

de Bruyn, Guy ;

Latka, Mary H. ;

Roux, Surita ;

Mathebula, Matsontso ;

Naicker, Nivashnee ;

Ducar, Constance ;

Carter, Donald K. ;

Puren, Adrien ;

Eaton, Niles ;

McElrath, M. Julie ;

Robertson, Michael ;

Corey, Lawrence ;

Kublin, James G. .

LANCET INFECTIOUS DISEASES, 2011, 11 (07) :507-515

[10] Using Multivalent Adenoviral Vectors for HIV Vaccination [J].

Gu, Linlin ;

Li, Zan C. ;

Krendelchtchikov, Alexandre ;

Krendelchtchikova, Valentina ;

Wu, Hongju ;

Matthews, Qiana L. .

PLOS ONE, 2013, 8 (03)

← 1 2 3 4 →